Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Urine miRNA transcriptome of prostate cancer patients [Training cohort]

ABSTRACT: Urine miRNA transcriptome of prostate cancer patients [Training cohort]

PROVIDER: PRJNA412693 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Urine miRNA transcriptome of prostate cancer patients [Training cohort]

Project description:Intra-individual stability of the urine miRNA transcriptome was examined by investigating longitudinal changes over time in a cohort of patients with localized prostate cancer. Using training and validation cohorts, urinary miRNA biomarkers are characterized and validated their utility to identify aggressive prostate cancer.

2019-10-24 | GSE104429 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

2019-10-24 | GSE104430 | GEO

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

2019-10-24 | GSE104431 | GEO

Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Validation cohort]

| PRJNA412692 | ENA

Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

Project description:Urine miRNA transcriptome of prostate cancer patients [Discovery cohort]

| PRJNA412691 | ENA

Prostate Cancer (PRC) training cohort for small RNA characterization

Project description:Prostate Cancer (PRC) training cohort for small RNA characterization

| PRJEB38300 | ENA

Urine miRNA transcriptome of prostate cancer patients

Project description:Urine miRNA transcriptome of prostate cancer patients

| PRJNA342023 | ENA

Prostate Cancer (PRC) training cohort for small RNA characterization

Project description:RNA sequencing study on prostate cancer (PRC) cohort for small RNA characterization across biofluids, tissue types and isolation techniques.

2022-06-01 | E-MTAB-8529 | biostudies-arrayexpress

Screening of urine methylation biomarker for prostate cancer detection

Project description:Methylation profiling of urine samples from patients with aggressive prostate cancer and without prostate cancer. Methylated DNA was immunoprecipitated with anti-methylcytosine antibodies from genomic DNA and detected by Affymetrix CytoScanHD chips. Methylated DNA was purified by 5-mC antibodies and Affymetrix CytoScanHD arrays were performed according to the manufacturer's protocols.

2019-03-07 | E-MTAB-7732 | biostudies-arrayexpress

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of post-operative outcome in prostate cancer patients

Project description:Background: New molecular biomarkers for prostate cancer (PC) prognosis are urgently needed. Ratio-based models are attractive, as they require no additional normalization. Here, we train and independently validate a novel 4-miRNA prognostic ratio model for PC. Patients and methods: By genome-wide miRNA expression profiling of PC tissue samples from 123 men who underwent radical prostatectomy (RP) (PCA123, training cohort), we identified six top candidate prognostic miRNAs and systematically tested their ability to predict post-operative biochemical recurrence (BCR). The best miRNA-based prognostic ratio model (MiCaP) was validated in two independent cohorts (PCA352 and PCA476) including >800 RP patients in total. Clinical endpoints were BCR and prostate cancer-specific survival (CSS). The prognostic potential of MiCaP was assessed by univariate and multivariate Cox-regression analyses and Kaplan-Meier analyses. Results: We identified a 4-miRNA ratio model, MiCaP (miR-23a-3p×miR-10b-5p)/(miR-133a×miR-374b-5p), that predicted time to BCR independently of routine clinicopathological variables in the training cohort (PCA123) and was successfully validated in two independent RP cohorts. In addition, MiCaP was a significant predictor of CSS in univariate analysis (HR 3·35 [95% CI 1·34 – 8·35], P=0·0096) and in multivariate analysis (HR 2·43 [95% CI 1·45 – 4·07], P=0·0210). Limitations include low mortality rates (CSS: 5.4%). Conclusions: We identified a novel 4-miRNA ratio model (MiCaP) with significant independent prognostic value in three RP cohorts, indicating promising potential to improve PC risk stratification.

2018-08-14 | GSE115402 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data